Hennion & Walsh Asset Management Inc. Sells 467 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Hennion & Walsh Asset Management Inc. decreased its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 1.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 37,413 shares of the company’s stock after selling 467 shares during the period. Hennion & Walsh Asset Management Inc. owned about 0.06% of Protagonist Therapeutics worth $1,684,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Privium Fund Management B.V. bought a new position in shares of Protagonist Therapeutics during the 1st quarter worth $3,299,000. GSA Capital Partners LLP increased its stake in shares of Protagonist Therapeutics by 179.8% in the first quarter. GSA Capital Partners LLP now owns 55,359 shares of the company’s stock worth $1,602,000 after purchasing an additional 35,571 shares in the last quarter. Sei Investments Co. raised its position in shares of Protagonist Therapeutics by 12.2% in the first quarter. Sei Investments Co. now owns 41,758 shares of the company’s stock valued at $1,208,000 after purchasing an additional 4,529 shares during the period. Russell Investments Group Ltd. bought a new stake in shares of Protagonist Therapeutics in the first quarter valued at approximately $35,000. Finally, ProShare Advisors LLC lifted its stake in shares of Protagonist Therapeutics by 9.2% during the 1st quarter. ProShare Advisors LLC now owns 14,345 shares of the company’s stock valued at $415,000 after buying an additional 1,206 shares in the last quarter. 98.63% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Protagonist Therapeutics news, CFO Asif Ali sold 14,203 shares of the firm’s stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $44.49, for a total transaction of $631,891.47. Following the sale, the chief financial officer now owns 34,960 shares in the company, valued at $1,555,370.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, Director William D. Waddill sold 8,000 shares of the company’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $45.00, for a total value of $360,000.00. Following the completion of the sale, the director now owns 12,000 shares of the company’s stock, valued at approximately $540,000. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Asif Ali sold 14,203 shares of the stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $44.49, for a total transaction of $631,891.47. Following the transaction, the chief financial officer now directly owns 34,960 shares in the company, valued at approximately $1,555,370.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 5.40% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts recently weighed in on PTGX shares. HC Wainwright lifted their price objective on shares of Protagonist Therapeutics from $40.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, September 12th. JPMorgan Chase & Co. boosted their price objective on Protagonist Therapeutics from $39.00 to $48.00 and gave the company an “overweight” rating in a research note on Thursday, July 25th. StockNews.com upgraded Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. TD Cowen upgraded Protagonist Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 25th. Finally, BTIG Research raised their price objective on shares of Protagonist Therapeutics from $41.00 to $51.00 and gave the company a “buy” rating in a research report on Wednesday, July 24th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Protagonist Therapeutics currently has an average rating of “Buy” and an average target price of $49.86.

Protagonist Therapeutics Trading Up 0.7 %

Shares of NASDAQ PTGX opened at $47.26 on Friday. The business has a 50-day moving average of $44.52 and a 200-day moving average of $36.60. The firm has a market capitalization of $2.77 billion, a price-to-earnings ratio of 19.37 and a beta of 2.17. Protagonist Therapeutics, Inc. has a 12 month low of $13.75 and a 12 month high of $48.32.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.50) EPS for the quarter, hitting analysts’ consensus estimates of ($0.50). The company had revenue of $4.17 million during the quarter, compared to analysts’ expectations of $40.00 million. On average, analysts predict that Protagonist Therapeutics, Inc. will post 2.32 earnings per share for the current year.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.